There are now numerous AI algorithms for electrophysiology. Jagmeet Singh, MD, examined how this advanced technology is being applied.

Bruce Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, said the new device could be "an important advancement for heart failure patients."

Daniel Cantillon, MD, explained why the positive performance of Abbott's Aveir dual-chamber leadless pacemaker could lead to considerable improvements in patient care. 

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.

The two new leadless pacemakers, the Micra AV2 and Micra VR2, feature much longer batteries than previous models. 

Samsung's smartwatches, already equipped with ECG technology, will now be able to alert users when signs of an irregular heart rhythm are detected.